The New World Health Organization-European Organization for Research and Treatment of Cancer Classification of Cutaneous Lymphomas

Advances in Dermatology

Volumn 22, Issue , 2006, Pages 259-277

  Ko, Christine J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LYMPHOMA; CLASSIFICATION; CUTANEOUS T CELL LYMPHOMA; HUMAN; LYMPHOMA; PATHOLOGY; REVIEW; SEZARY SYNDROME; SKIN TUMOR; WORLD HEALTH ORGANIZATION;

HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; SEZARY SYNDROME; SKIN NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 33845625761     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2006.09.006     Document Type: Review

References (121)

1. Vakeva L., Sarna S., Vaalasti A., et al. A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides. Acta Derm Venereol 85 (2005) 318-323
2. Lok C., Viseux V., Denoeux J.P., et al. Post-transplant cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 56 (2005) 137-145
3. Bouwhuis S.A., Davis M.D., el-Azhary R.A., et al. Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 52 (2005) 991-996
4. El-Azhary R.A., and Bouwhuis S.A. Oral bexarotene in a therapy-resistant Sezary syndrome patient: observations on Sezary cell compartmentalization. Int J Dermatol 44 (2005) 25-29
5. Budgin J.B., Richardson S.K., Newton S.B., et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 141 (2005) 315-321
6. Querfeld C., Rosen S.T., Guitart J., et al. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 12 (2005) 273-278
7. McFarlane V., Friedmann P.S., and Illidge T.M. What's new in the management of cutaneous T-cell lymphoma?. Clin Oncol (R Coll Radiol) 17 (2005) 174-184
8. Weber F., Schmuth M., Sepp N., et al. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm Venereol 85 (2005) 329-332
9. Molina A., Zain J., Arber D.A., et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (2005) 6163-6171
10. Rupoli S., Goteri G., Pulini S., et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 75 (2005) 136-145
11. Gambichler T., Breuckmann F., Boms S., et al. Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 52 (2005) 660-670
12. Whittam L.R., Calonje E., Orchard G., et al. CD8-positive juvenile onset mycosis fungoides: an immunohistochemical and genotypic analysis of six cases. Br J Dermatol 143 (2000) 1199-1204
13. Wain E.M., Orchard G.E., Whittaker S.J., et al. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 98 (2003) 2282-2290
14. Stevens S.R., Ke M.S., Birol A., et al. A simple clinical scoring system to improve the sensitivity and standardization of the diagnosis of mycosis fungoides type cutaneous T-cell lymphoma: logistic regression of clinical and laboratory data. Br J Dermatol 149 (2003) 513-522
15. Pimpinelli N., Olsen E.A., Santucci M., et al. Defining early mycosis fungoides. J Am Acad Dermatol 53 (2005) 1053-1063
16. Massone C., Kodama K., Kerl H., et al. Histopathologic features of early (patch) lesions of mycosis fungoides. A morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 29 (2005) 550-560
17. Glusac E.J. Criterion by criterion, MF. Am J Dermatopathol 25 (2003) 264
18. Santucci M., Biggeri A., Feller A.C., et al. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: an EORTC cutaneous lymphoma project group study. Arch Dermatol 136 (2000) 497-502
19. Guitart J., Kennedy J., Ronan S., et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol 28 (2001) 174-183
20. Ortonne N., Buyukbabani N., Delfau-Larue M.H., et al. Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides. Mod Pathol 16 (2003) 857-862
21. Bergman R. How useful are T-cell receptor gene rearrangement studies as an adjunct to the histopathologic diagnosis of mycosis fungoides?. Am J Dermatopathol 1 (1999) 498-502
22. Wienberg J.M., Rook A.H., and Lessin S.R. Molecular diagnosis of lymphocytic infiltrates in the skin. Arch Dermatol 129 (1993) 1491-1500
23. Muche J.M., Sterry W., Gellrich S., et al. Peripheral blood T-cell clonality in mycosis fungoides and nonlymphoma controls. Diagn Mol Pathol 12 (2003) 142-150
24. Alessi E., Coggi A., Venegoni L., et al. The usefulness of clonality for the detection of cases clinically and/or histopathologically not recognized as cutaneous T-cell lymphoma. Br J Dermatol 153 (2005) 368-371
25. Tok J., Szabolcs M.J., Silvers D.N., et al. Detection of clonal T-cell receptor gamma chain gene rearrangements by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE) in archival specimens from patients with early cutaneous T-cell lymphoma: correlation of histologic findings with PCR/DGGE. J Am Acad Dermatol 38 (1998) 453-460
26. Wood G.S., Tung R.M., Haeffner A.C., et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary Syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 103 (1994) 34-41
27. Cordel N., Lenormand B., Courville P., et al. Usefulness of cutaneous T-cell clonality analysis for the diagnosis of cutaneous T-cell lymphoma in patients with erythroderma. Arch Pathol Lab Med 129 (2005) 372-376
28. Wood G.S., and Greenberg H.L. Diagnosis, staging, and monitoring of cutaneous T-cell lymphoma. Dermatol Ther 16 (2003) 269-275
29. Tracey L., Villuendas R., Dotor A.M., et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 102 (2003) 1042-1050
30. Querfeld C., Rosen S.T., Kuzel T.M., et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (2005) 305-311
31. Kaye F.J., Bunn Jr. P.A., Steinberg S.M., et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (1989) 1784-1790
32. Juarez T., Isenhath S.N., Polissar N.L., et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 141 (2005) 1107-1113
33. Meissner K., Michaelis K., Rehpenning W., et al. Epidermal Langerhans' cell densities influence survival in mycosis fungoides and Sezary syndrome. Cancer 65 (1990) 2069-2073
34. Hoppe R.T., Medeiros L.J., Warnke R.A., et al. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32 (1995) 448-453
35. Klemke C.D., Mansmann U., Poenitz N., et al. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 153 (2005) 118-124
36. Ponti R., Quaglino P., Novelli M., et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol 153 (2005) 565-573
37. Assaf C., Hummel M., Steinhoff M., et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood 105 (2005) 503-510
38. Abeni D., Frontani M., Sampogna F., et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 153 (2005) 324-330
39. Dmitrovsky E., Matthews M.J., Bunn P.A., et al. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol 5 (1987) 208-215
40. Tancrede-Bohin E., Ionescu M.A., de La Salmoniere P., et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 140 (2004) 1057-1061
41. Franck N., Carlotti A., Gorin I., et al. Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol 141 (2005) 353-356
42. Ionescu M.A., Rivet J., Daneshpouy M., et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 52 (2005) 32-39
43. Kazakov D.V., Burg G., and Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 18 (2004) 397-415
44. Thein M., Ravat F., Orchard G., et al. Syringotropic cutaneous T-cell lymphoma: an immunophenotypic and genotypic study of five cases. Br J Dermatol 151 (2004) 216-226
45. Venturini A., Zane C., Rodella R., et al. Syringotropic cutaneous T cell lymphoma treated with PUVA therapy. Eur J Dermatol 15 (2005) 262-264
46. Tan S.H., Sim C.S., Ong B.H., et al. Follicular mycosis fungoides mimicking a cutaneous B-cell lymphoproliferative disorder. Australas J Dermatol 45 (2004) 188-191
47. Pereyo N.G., Requena L., Galloway J., et al. Follicular mycosis fungoides: a clinicohistopathologic study. J Am Acad Dermatol 36 (1997) 563-568
48. Van Doorn R., Scheffer E., and Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. A clinicopathologic and follow-up study of 51 patients. Arch Dermatol 138 (2002) 191-198
49. Klemke C.D., Dippel E., Assaf C., et al. Follicular mycosis fungoides. Br J Dermatol 141 (1999) 137-140
50. Fink-Puches R., Chott A., Ardigo M., et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 21 (2004) 525-533
51. Yagi H., Hagiwara T., Shirahama S., et al. Disseminated pagetoid reticulosis: need for long term follow-up. J Am Acad Dermatol 30 (1994) 345-349
52. Haghighi B., Smoller B.R., LeBoit P.E., et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 13 (2000) 502-510
53. Gadzia J., and Kestenbaum T. Granulomatous slack skin without evidence of a clonal T-cell proliferation. J Am Acad Dermatol 50 (2004) S4-S8
54. Vonderheid E.C., Boselli C.M., Conroy M., et al. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 124 (2005) 651-661
55. Knol A.C., Guilloux Y., Quereux G., et al. CD8(+) T lymphocytes reactive against Epstein-Barr virus antigens in skin lesions of a patient with Sezary syndrome. J Am Acad Dermatol 53 (2005) 897-900
56. Vonderheid E.C., Bernengo M.G., Burg G., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46 (2002) 95-106
57. Trotter M.J., Whittaker S.J., Orchard G.E., et al. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol 24 (1997) 286-291
58. Kim E.J., Hess S., Richardson S.K., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115 (2005) 798-812
59. Narducci M.G., Scala E., Bresin A., et al. Skin-homing of Sezary cells involves SDF-1-CXCR4 signaling and downregulation of CD26/dipeptidylpeptidase IV. Blood 107 (2006) 1108-1115
60. Vonderheid E.C., and Bernengo M.G. The Sezary syndrome: hematologic criteria. Hematol Oncol Clin North Am 17 (2003) 1367-1389
61. Kari L., Loboda A., Nebozyn M., et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197 (2003) 1477-1488
62. Wasik M.A., Vonderheid E.C., Bigler R.D., et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132 1 (1996) 42-47
63. Foulc P., N'Guyen J.M., and Dreno B. Prognostic factors in Sezary syndrome: a study of 28 patients. Br J Dermatol 149 (2003) 1152-1158
64. Paulli M., and Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica 89 11 (2004) 1372-1388
65. Vergier B., Beylot-Barry M., Pulford K., et al. Statistical evaluation of diagnostic and prognostic features of CD30 + cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 22 (1998) 1192-1202
66. Nijsten T., Curiel-Lewandrowski C., and Kadin M.E. Lymphomatoid papulosis in children. A retrospective cohort study of 35 cases. Arch Dermatol 140 (2004) 306-312
67. Clarke L.E., Bayerl M.G., Bruggeman R.D., et al. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol 29 (2005) 452-459
68. Belijards R.C., Kaudewitz P., Berti E., et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study on 47 cases. Cancer 71 (1993) 2097-2104
69. Liu H.L., Hoppe R.T., Kohler S., et al. CD30 + cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49 (2003) 1049-1058
70. Shabrawi-Caelen L., Kerl H., and Cerroni L. Lymphomatoid papulosis. Reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 140 (2004) 441-447
71. Paulli M., Berti E., Rosso R., et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 13 (1995) 1343-1354
72. Nascimento A.F., Pinkus J.L., and Pinkus G.S. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and non-hematopoietic malignant neoplasms. Am J Clin Pathol 121 (2004) 709-717
73. Gallardo F., Costa C., Bellosillo B., et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol 84 (2004) 463-46
74. Bekkenk M.W., Geelen F.A., van Voorst Vader P.C., et al. Primary and secondary cutaneous CD30 + lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95 (2000) 3653-3661
75. Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol 78 (2005) 232-239
76. Yamaguchi T., Ohshima K., Tsuchiya T., et al. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma. Eur J Dermatol 13 (2003) 553-559
77. Yagi H., Takigawa M., and Hashizuma H. Cutaneous type of adult T cell leukemia/lymphoma: a new entity among cutaneous lymphomas. J Dermatol 30 (2003) 641-643
78. Yamaguchi T., Ohshima K., Karube K., et al. Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/lymphoma. Br J Dermatol 152 (2005) 76-81
79. Massone C., Chott A., Metze D., et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin. A morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 28 (2004) 719-735
80. Ghobrial I.M., Weenig R.H., Pittlekow M.R., et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 46 (2005) 703-708
81. Chan J.K., Sin V.C., Wong K.F., et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89 (1997) 4501-4513
82. Barrionuevo C., Anderson V.M., Zevallos-Giampietri E., et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 10 (2002) 7-14
83. Emile J.F., Boulland M.L., Haioun C., et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87 (1996) 1466
84. Jaffe E.S. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 87 (1996) 1207-1210
85. Savoia P., Fierro M.T., Novelli M., et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 137 (1997) 966-971
86. Gniadecki R., Rossen K., Ralfkier E., et al. CD56+ lymphoma with skin involvement. Clinicopathologic features and classification. Arch Dermatol 140 (2004) 427-436
87. DiGiuseppe J.A., Louie D.C., Williams J.E., et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol 21 (1997) 1223-1230
88. Verma S., Frambach G.E., Seilstad K.H., et al. Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol 32 (2005) 474-483
89. El-Helw L., Goodwin S., Slater D., et al. Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003). Int J Oncol 25 (2004) 1453-1458
90. Bogle M.A., Riddle C.C., Triana E.M., et al. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 53 (2005) 479-484
91. Kerl H., Kodama K., and Cerroni L. Diagnostic principles and new developments in primary cutaneous B-cell lymphomas. Dermatol Sci 34 (2004) 167-175
92. Ulutin H.C., Ozturk B., Onguru O., et al. Treatment of primary cutaneous B-cell lymphoma with radiotherapy. Radiat Med 23 (2005) 292-295
93. Rijlaarsdam J.U., Toonstra J., Meijer C.J.L.M., et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 14 (1996) 549-555
94. Grange F., Bekkenk M.W., Wechsler J., et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19 (2001) 3602-3610
95. Fink-Puches R., Wolf I.H., Zalaudek I., et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 52 (2005) 847-853
96. Gellrich S., Muche J.M., Wilks A., et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 153 (2005) 167-173
97. Terrier B., Aouba A., Vasiliu V., et al. Intravascular lymphoma associated with haemophagocytic syndrome: a very rare entity in western countries. Eur J Haematol 75 (2005) 341-345
98. Roguedas A.M., Watier H., Paintaud G., et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 152 (2005) 541-544
99. Rawal Y.B., Nuovo G.J., Frambach G.E., et al. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 32 (2005) 616-621
100. Hoefnagel J.J., Vermeer M.H., Jansen P.M., et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 141 (2005) 1139-1145
101. Cerroni L., Signoretti S., Hofler G., et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 21 (1997) 1307-1315
102. Servitje O., Gallardo F., Estrach T., et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol 147 (2002) 1147-1158
103. Li C., Inagaki H., Kuo T.T., et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 Asian cases. Am J Surg Pathol 27 (2003) 1061-1069
104. Arai E., Shimizu M., and Hirose T. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis. Hum Pathol 36 (2005) 505-511
105. Bergman R., Kurtin P.J., Gibson L.E., et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 137 (2001) 432-439
106. Slater D.N. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 153 (2005) 874-880
107. Kodama K., Massone C., Chott A., et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106 (2005) 2491-2497
108. Cerroni L., Arzberger E., Putz B., et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 95 (2000) 3922-3928
109. Cerroni L., and Kerl H. Primary cutaneous follicular lymphoma. Arch Dermatol 137 (2001) 489-490
110. De Leval L., Harris N.L., Longtime J., et al. Cutaneous B-cell lymphomas of follicular and marginal zone types. Use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 25 (2001) 732-741
111. Leinweber B., Colli C., Chott A., et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol 26 1 (2004) 4-13
112. Goodlad J.R., Krajewski A.S., Batsone P.J., et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol 27 (2003) 1538-1545
113. Brogan B.L., Zic J.A., Kinney M.C., et al. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol 49 (2003) 223-228
114. Paulli M., Viglio A., Vivenza D., et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol 33 (2002) 937-943
115. Sundram U., Kim Y., Mraz-Gernhard S., et al. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 32 (2005) 227-234
116. Wiesner T., Streubel B., Huber D., et al. Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases. Am J Surg Pathol 29 (2005) 666-673
117. Santucci M., and Pimpinelli N. Primary cutaneous B-cell lymphomas. Current concepts. I. Hematologica 89 (2004) 1360-1371
118. Ferreri A.J.M., Campo E., Seymour J.F., et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the "cutaneous variant". Br J Haematol 127 (2004) 173-183
119. Cerroni L., Zalaudek I., and Kerl H. Intravascular large B-cell lymphoma colonizing cutaneous hemangiomas. Dermatology 209 (2004) 132-134
120. Murase T., and Nakamura S. An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma 33 (1999) 459-473
121. Whittaker S.J., Marsden J.R., Spittle M., et al. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 149 (2003) 1095-1107